Search

Displaying results 6241 - 6250 of 8171 in total
  1. Drug

    Belnacasan

    go.drugbank.com/drugs/DB05507
    Investigational

    VX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.

  2. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  3. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.

  4. Drug

    Chikungunya vaccine (live, attenuated)

    go.drugbank.com/drugs/DB18701
    ApprovedInvestigational

    Infection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia.

  5. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  6. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    An animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].

  7. Drug

    Albinterferon Alfa-2B

    go.drugbank.com/drugs/DB05396
    Investigational

    The drug was under investigation as an alternative to pegylated IFN-α-2a for the treatment of hepatitis C. … In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they ceased development of the drug.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  8. Drug

    Afabicin

    go.drugbank.com/drugs/DB15268
    Investigational

    Afabicin is under investigation in clinical trial NCT03723551 (Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

  9. Drug

    RAPA-501-Allo

    go.drugbank.com/drugs/DB15890
    Investigational

    RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed _ex vivo_ in a process that involves de-differentiation and re-differentiation.[L16483]

  10. Drug

    Temoporfin

    go.drugbank.com/drugs/DB11630
    Approved

    Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2001. It is currently available unde...